SGH
Sivik Global Healthcare Portfolio holdings
AUM
$224M
This Quarter Return
+9.08%
1 Year Return
+5.3%
3 Year Return
+45.33%
5 Year Return
+103.79%
10 Year Return
+430.94%
AUM
$233M
AUM Growth
+$233M
(-19%)
Cap. Flow
-$85.7M
Cap. Flow
% of AUM
-36.74%
Top 10 Holdings %
Top 10 Hldgs %
36.18%
Holding
60
New
18
Increased
2
Reduced
24
Closed
14
Top Buys
| 1 |
SPDR S&P Biotech ETF
XBI
|
$11.2M |
| 2 |
Elevance Health
ELV
|
$8.11M |
| 3 |
Universal Health Services
UHS
|
$7.78M |
| 4 |
Pfizer
PFE
|
$5.91M |
| 5 |
AbbVie
ABBV
|
$5.42M |
Top Sells
| 1 |
UnitedHealth
UNH
|
$26.4M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$10.3M |
| 3 |
Medtronic
MDT
|
$10M |
| 4 |
Smith & Nephew
SNN
|
$8.57M |
| 5 |
CTLT
CATALENT, INC.
CTLT
|
$8.1M |
Sector Composition
| 1 | Healthcare | 95.2% |
| 2 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
SPDR S&P Biotech ETF
XBI
$5.07B
| $11.2M | 4.8% | +100,000 | New | +$11.2M |
|
|
2
UnitedHealth
UNH
$281B
| $8.79M | 3.76% | 17,500 -52,500 | -75% | -$26.4M |
|
3
McKesson
MCK
$85.4B
| $8.7M | 3.73% | 35,000 -10,000 | -22% | -$2.49M |
|
4
Thermo Fisher Scientific
TMO
$186B
| $8.34M | 3.57% | 12,500 -2,500 | -17% | -$1.67M |
|
5
Danaher
DHR
$147B
| $8.23M | 3.52% | 25,000 -5,000 | -17% | -$1.65M |
|
6
Humana
HUM
$36.5B
| $8.12M | 3.48% | 17,500 +5,000 | +40% | +$2.32M |
|
|
7
Elevance Health
ELV
$71.8B
| $8.11M | 3.48% | +17,500 | New | +$8.11M |
|
|
8
Universal Health Services
UHS
$11.6B
| $7.78M | 3.33% | +60,000 | New | +$7.78M |
|
9
Eli Lilly
LLY
$657B
| $7.6M | 3.25% | 27,500 -7,500 | -21% | -$2.07M |
|
10
Avantor
AVTR
$9.18B
| $7.59M | 3.25% | 180,000 -30,000 | -14% | -$1.26M |
|
11
Tenet Healthcare
THC
$16.3B
| $7.35M | 3.15% | 90,000 +10,000 | +13% | +$817K |
|
12
Labcorp
LH
$23.1B
| $7.07M | 3.03% | 22,500 -2,500 | -10% | -$786K |
|
13
Abbott
ABT
$231B
| $7.04M | 3.02% | 50,000 -20,000 | -29% | -$2.81M |
|
14
Cencora
COR
$56.5B
| $6.98M | 2.99% | 52,500 -5,000 | -9% | -$664K |
|
15
HCA Healthcare
HCA
$94.5B
| $6.93M | 2.97% | 26,987 -28,013 | -51% | -$7.2M |
|
16
Boston Scientific
BSX
$156B
| $6.8M | 2.91% | 160,000 -60,000 | -27% | -$2.55M |
|
17
Baxter International
BAX
$12.7B
| $6.44M | 2.76% | 75,000 -40,000 | -35% | -$3.43M |
|
|
18
Pfizer
PFE
$141B
| $5.91M | 2.53% | +100,000 | New | +$5.91M |
|
19
Charles River Laboratories
CRL
$8.04B
| $5.65M | 2.42% | 15,000 -5,000 | -25% | -$1.88M |
|
|
20
AbbVie
ABBV
$372B
| $5.42M | 2.32% | +40,000 | New | +$5.42M |
|
21
Globus Medical
GMED
$8.27B
| $5.42M | 2.32% | 75,000 -20,000 | -21% | -$1.44M |
|
22
Zimmer Biomet
ZBH
$21B
| $5.4M | 2.31% | +42,500 | New | +$5.4M |
|
23
CVS Health
CVS
$92.8B
| $5.16M | 2.21% | +50,000 | New | +$5.16M |
|
24
Johnson & Johnson
JNJ
$427B
| $5.13M | 2.2% | 30,000 -40,000 | -57% | -$6.84M |
|
25
Becton Dickinson
BDX
$55.3B
| $4.4M | 1.89% | 17,500 -7,500 | -30% | -$1.89M |
|